Veranova is your next great decision
Discover new ways to advance your science with Veranova.
Contact usSubathra Ramamoorthy, Veranova’s Associate Principal Scientist in analytical research and development, named five triggers that force full structural work on an impurity, and said the short-duration provision in ICH M7 is the one teams overlook. On Sept. 24 FDA made that provision available for nitrosamines for the first time, with factors up to 80 times the lifetime limit.
Subathra laid out a phase-by-phase approach to impurity characterization in two interviews with Pharmaceutical Technology recorded at AAPS PharmSci 360 in New Orleans, published Oct. 30 and Nov. 2. By Phase 3, she said, any impurity above the identification threshold needs complete structural elucidation backed by a qualified reference standard. Her second interview covered what breaks in a potent-API laboratory. Carryover there shows up as a result, because the work happens inside isolators with milligram quantities available.
Discover new ways to advance your science with Veranova.
Contact us